Charles Schwab
IMDX

Charles Schwab’s Insight Molecular Diagnostics IMDX Stock Holding History

Charles Schwab’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,114
Closed -$22.1K – 3661
2023
Q1 		$22.1K Hold
3,114
– – ﹤0.01% 3498
2022
Q4 		$20K Hold
3,114
– – ﹤0.01% 3502
2022
Q3 		$46K Hold
3,114
– – ﹤0.01% 3346
2022
Q2 		$57K Sell
3,114
-4,895
-61% -$111K ﹤0.01% 3377
2022
Q1 		$239K Hold
8,009
– – ﹤0.01% 3275
2021
Q4 		$348K Hold
8,009
– – ﹤0.01% 3257
2021
Q3 		$571K Sell
8,009
-1,032
-11% -$94.9K ﹤0.01% 3100
2021
Q2 		$1.04M Sell
9,041
-86
-0.9% -$8.4K ﹤0.01% 2916
2021
Q1 		$948K Buy
9,127
+1,083
+13% +$103K ﹤0.01% 2879
2020
Q4 		$385K Buy
8,044
+1,060
+15% +$38.9K ﹤0.01% 3075
2020
Q3 		$195K Buy
6,984
+1,853
+36% +$53.1K ﹤0.01% 3181
2020
Q2 		$196K Buy
5,131
+2,427
+90% +$125K ﹤0.01% 3170
2020
Q1 		$133K Hold
2,704
– – ﹤0.01% 3079
2019
Q4 		$122K Hold
2,704
– – ﹤0.01% 3087
2019
Q3 		$114K Sell
2,704
-193
-7% -$7.58K ﹤0.01% 3088
2019
Q2 		$145K Buy
2,897
+2,234
+337% +$186K ﹤0.01% 3111
2019
Q1 		$53K Buy
+663
New +$42.8K ﹤0.01% 3116

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab's IMDX Position: Q2 2023 in Review

Charles Schwab sold out of Insight Molecular Diagnostics (IMDX) in Q2 2023, closing a stake of 3,114 shares — an estimated $22.1K sold.

Charles Schwab first reported a position in IMDX in Q1 2019 and held it in 17 quarters. The position peaked at $1.04M in Q2 2021. 47 funds tracked by Wall St. Rank hold IMDX as of Q2 2023.

  • Charles Schwab reported no remaining Insight Molecular Diagnostics position as of Q2 2023 after selling out during the quarter.
  • Charles Schwab sold 3,114 Insight Molecular Diagnostics shares in Q2 2023, an estimated $22.1K.
  • Charles Schwab first reported a position in Insight Molecular Diagnostics in Q1 2019 and held it in 17 quarters.
  • Charles Schwab's Insight Molecular Diagnostics position peaked at $1.04M in Q2 2021.
  • 47 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2023.

Based on Charles Schwab's 13F filing for Q2 2023, filed 10 Aug 2023.